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Abstract
Background: Neuropeptide FF (NPFF) plays a role in physiological pain sensation and opioid
analgesia. For example, NPFF potentiates opiate-induced analgesia and the delta opioid receptor
antagonist naltrindole inhibits NPFF-induced antinociception. The nature of the interactions
between NPFF and opioid receptors seems to be complex and the molecular mechanisms behind
the observed physiological effects are not known.
Results: We used a stable Chinese hamster ovary cell line expressing c-MYC-tagged human delta
opioid receptor to study the interactions at the molecular level. Our results imply that NPFF can
directly modulate the activation of delta opioid receptor in the absence of NPFF receptors. The
modulatory effect, though only moderate, was consistently detected with several methods. The
agonist-induced receptor trafficking was changed in the presence of (1DMe)NPYF, a stable NPFF-
analogue. (1DMe)NPYF enhanced the receptor activation and recovery; opioid antagonists
inhibited the effects, indicating that they were delta opioid receptor-mediated. The binding
experiments with a novel ligand, Terbium-labeled deltorphin I, showed that (1DMe)NPYF
modulated the binding of delta opioid receptor ligands. The levels of phosphorylated mitogen-
activated protein kinase and intracellular cAMP were studied to clarify the effects of NPFF on the
opioid signaling mechanisms. Application of (1DMe)NPYF together with a delta opioid receptor
agonist enhanced the signaling via both pathways studied. Concomitantly to the receptor trafficking,
the time-course of the activation of the signaling was altered.
Conclusion: In addition to working via indirect mechanisms on the opioid systems, NPFF may
exert a direct modulatory effect on the delta opioid receptor. NPFF may be a multi-functional
neuropeptide that regulates several neuronal systems depending on the site of action.
Background
Neuropeptide FF (NPFF) belongs to a family of RFamide
peptides and was originally isolated from bovine brain [1-
3]. It has a wide range of functions, including effects on
pain mechanisms [1,4], opioid tolerance [5], cardiovascu-
lar regulation [6] and neuroendocrinological function [7].
At the physiological level NPFF seems to have both a
direct analgesic effect and a modulatory effect on the opi-
oid system. Some of the effects may be mediated via the
NPFF receptors as two such receptors, NPFF1R and
NPFF2R, have been identified [17-19]. Both NPFF1R and
NPFF2R are expressed in the central nervous system and
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NPFF binds to both of them [17-20]. Also the other RFa-
mide peptides bind to the NPFF receptors with varying
affinities [21], and therefore the exact nature of the recep-
tor-ligand interactions between RFamides and their recep-
tors is still unclear.
The interaction between NPFF and opioid system in pain
and analgesia seems to be complex in nature and the
molecular mechanisms behind the observed physiologi-
cal effects are not known. Binding studies have shown that
NPFF does not displace opioid receptor ligands from any
of the opioid receptor subtypes and opiates do not bind to
NPFF binding sites [16]. However, many studies suggest
that NPFF mechanisms are functionally coupled to the
opioid system [for a review see ref. [8]]. In the rat spinal
cord, the highest NPFF-like immunoreactivity is found in
the superficial layers of the dorsal horn, an area involved
in the nociceptive processes and pain mechanisms [9-11].
NPFF has been designated as a morphine modulatory
peptide since it is able to influence the actions of opioid
peptides within spinal cord and brain [8,12,13]. NPFF dis-
plays both anti-opioid and opioid-like effects depending
on the route of administration. Supraspinal administra-
tion of NPFF attenuates opioid antinociception [1] and
precipitates opioid withdrawal syndrome [5]. Intrathe-
cally administered NPFF causes long-lasting analgesia,
which is reduced by both naloxone and naltrindole [4].
NPFF in the periaqueductal grey produces a selective
attenuation of tactile allodynia in neuropathic rats [14]
that could be mediated indirectly by naloxone-sensitive
opioid mechanisms [15]. In pontine parabrachial nucleus
NPFF modulates synaptic transmission through interac-
tion with presynaptic DOR, providing evidence for the
cellular mechanisms of the analgesic action of NPFF at the
supraspinal level [12].
Delta opioid receptor (DOR) belongs to the family of G-
protein coupled, seven trans-membrane receptors
[22,23]. DOR couples to the pertussis toxin -sensitive Gi/
o-type of heterotrimeric G-proteins. The receptor can reg-
ulate several effector systems, including adenylyl cyclase
activity [22,24], the phosphorylation of mitogen activated
protein kinases (MAPK) [25], voltage-gated calcium and
potassium channels [26] and phospholipase C [27]. In
CHO-cells the DOR-induced activation of MAPK-pathway
is predominantly mediated by the Gβγ -subunit of Gi/o
[28] whereas adenylate cyclase response is mediated by
the Gα i/o-subunit [24]. The involvement of DOR in anal-
gesia has been shown using many pain models [29] and
agonists acting at DOR have a strong antinociceptive
effect [30]. The agonist stimulation causes rapid desensiti-
zation of the receptor by phosphorylation [31], which in
turn produces the uncoupling of the receptor from its G-
protein. The phosphorylation can be followed by endocy-
tosis of the ligand-receptor complex [32] but the desensi-
tization may occur also without receptor internalization
[31]. The internalized receptor is either degraded or recy-
cled back to the cell membrane [32,33].
We constructed a stable Chinese hamster ovary cell line
expressing c-MYC-tagged human DOR (MYChDOR). The
cell line was used as a model system to learn about the
mechanisms involved in the interactions between NPFF
and hDOR at the cellular and molecular level.
Results
Characterization of the cell line
The cellular localization of the expressed c-MYC-tagged
delta opioid receptors in the stable CHO-K1 clone was
analyzed with immunocytochemistry. The cells were
stained with an anti-c-MYC antibody, detected with a flu-
orescent secondary antibody and analyzed with a laser
scanning confocal microscope. The untransfected wild
type cells did not show any fluorescence when stained
similarly as the CHO/MYChDOR cells and the pre-
absorption of the antibody solution with the c-MYC-pep-
tide before immunocytochemistry removed all signal in
the CHO/MYChDOR cells, implying that the antibody
bound specifically to the MYC-tagged receptor (data not
shown). In the CHO/MYChDOR cells a clear fluorescence
signal was seen on the cell surface (Figure 1A) and DOR
agonists induced the internalization of the receptor (Fig-
ure 1B &1C).
The receptor density and ligand binding characteristics of
the expressed receptor were determined with 3H-diprenor-
phine binding assay. The observed values for KD and BMAX
were 0.203 ± 0.090 nM and 0.530 ± 0.042 pmol/mg pro-
tein (318000 receptors/cell), respectively. The functional-
ity of cells expressing MYC-tagged DOR was shown with
the inhibition of forskolin-stimulated accumulation of
cAMP and phosphorylation of ERK2. DPDPE dose-
dependently inhibited the forskolin-induced accumula-
tion of cAMP and similarly increased the phosphorylation
of the ERK2 (data not shown and see below).
The possible presence of NPFF1R and NPFF2R in the
CHO-K1 cells was studied with several methods. First the
cells were studied with immunocytochemistry and confo-
cal microscopy. Several antibodies against NPFF receptors
were used. In the Figure 2A–D the results obtained with
two antibodies are shown. The pre-absorption of the anti-
body solutions with the antigenic peptide before immu-
nocytochemistry removed all immunoreactivity from
CHO-K1/hNPFF2R cells in the case of each antibody
tested, implying that the antibodies recognized specifi-
cally the antigen. No immunoreactivity was found in the
untransfected CHO-K1 cells (Figure 1B &1D), which fur-
ther suggested that the antibodies bound specifically to
the hNPFF2R. Next the cells were analyzed with RT-PCR.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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cDNA made of total RNA from human medial hypothala-
mus and human placenta were used as positive controls
for NPFF1R and NPFF2R, respectively, since a relatively
high level of receptor expression has been shown in these
tissues [17-20]. NPFF1R and NPFF2R specific primers
based on human and mouse receptor sequences were used
in the analysis. No PCR products were obtained from the
CHO-K1 cDNA using conditions where the controls
tested positive (Figure 1E &1F). The binding of NPFF
receptor specific radioligand 125I-(1DMe)NPYF to the
CHO-K1 cells was tested. The cells did not bind the 125I-
(1DMe)NPYF (Figure 2G). Cell membranes of a commer-
cial hNPFF2R expressing CHO-K1 cell line (Euroscreen
S.A., Brussels, Belgium) were used as a positive control in
the experiment (Figure 2H). 125I-(1DMe)NPYF bound to
these cell membranes with the same affinity as reported
by the supplier and as observed previously in our labora-
tory [21]. In addition, the NPFF-analogue alone did not
affect any of the tested parameters, such as cAMP or MAPK
(see below), which further supported the absence of NPFF
receptors in CHO-K1 cells.
Effect of (1DMe)NPYF on the agonist activated DOR 
trafficking
The CHO-K1 cells expressing MYC-tagged DOR were
treated with 100 nM DPDPE (or DeltI) with or without
100 nM (1DMe)NPYF for 0, 5, 10 or 30 min at 37°C. The
receptor trafficking was analyzed with fluorescence associ-
ated cell sorting, FACS. After the drug treatments, the cell
surface receptors were detected with an anti-MYC-anti-
body and a fluorescent secondary antibody. At the basal
state the amount of the cell surface fluorescence, which
should reflect the amount of DORs located on the cell
membrane, was observed to be variable between runs. To
control the variation the cells were cultured for a fixed
period of time after the last passage prior to internaliza-
tion studies and grown into 80–90 % confluence. The
cells were let to recover at 37°C after they were collected
from the culture plates and before they were used for the
experiments, to ensure that the receptor number on the
cell membrane was balanced. Some constitutive receptor
trafficking was still observed and therefore the treated
cells at each time-point were compared to time-matched
untreated control cells in order to distinguish between
constitutive and ligand-induced receptor trafficking.
As seen in the FACS analysis, (1DMe)NPYF (100 nM)
alone did not induce receptor internalization at any time-
point tested (Figure 3). However, after 30 min treatment
with the NPFF analogue somewhat higher fluorescence
was detected on the cell surface as in the time-matched
control cells. Already after 5 min treatment with 100 nM
DPDPE or with 100 nM DPDPE and 100 nM
(1DMe)NPYF the cell surface fluorescence was signifi-
cantly different from the untreated control cells, indicative
of ligand-induced internalization of the receptor. There
was no significant difference between the treatments at
this time-point although the double treatment with 100
Characterization of the CHO-K1 cells stably expressing MYC-tagged human DOR Figure 1
Characterization of the CHO-K1 cells stably expressing MYC-tagged human DOR. A. The cell surface receptors 
were visualized with an anti-MYC antibody and a fluorescent secondary antibody. B. The cells were treated with 100 nM 
DPDPE for 10 min at +37°C after which the remaining cell surface receptors were visualized with an anti-MYC antibody and a 
fluorescent secondary antibody. C. The cells were stimulated with 100 nM DeltI for 5 min at 37°C, permeabilized with saponin 
and the receptors were visualized with an anti-MYC antibody and a fluorescent secondary antibody. All the images are 0.5 µm 
confocal sections at the mid-nuclear level. Representative images are shown. Scale bar 20 µm.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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CHO-K1 cells do not express NPFF receptors Figure 2
CHO-K1 cells do not express NPFF receptors. The presence or absence of NPFF receptors was analyzed with immuno-
cytochemistry, RT-PCR and radioligand binding assay. A. CHO-K1 cells expressing hNPFF2R showed intense fluorescence 
when immunolabeled with an anti NPFF2R antibody detecting the C-terminus of the receptor. B. In the same conditions, the 
C-terminally oriented antibody did not label nontransfected CHO-K1 cells. C. The NPFF2R expression was also studied with 
an anti-NPFF2R antibody that binds to the N-terminus of the receptor. Again, in CHO-K1 cells expressing hNPFF2R immuno-
reactivity for the receptor was found. D. The N-terminally oriented NPFF2R antibody did not detect NPFF2R immunoreactiv-
ity in the nontransfected CHO-K1 cells. All the images are 0.5 µm confocal sections at the mid-nuclear level. Representative 
images are shown. Scale bar 20 µm. RT-PCR analysis gave further support for the absence of the NPFF receptors in CHO-K1 
cells. E. cDNA from CHO-K1 cells were analyzed with hNPFF1 receptor specific primers and no PCR-product was obtained; 
human hypothalamus was used as a positive control (expected size of the PCR-product ~350 bp). F. The RT-PCR analysis of 
CHO-K1 cDNA did not give any PCR-product with hNPFF2R specific primers either; human placenta was used as a positive 
control (expected size of the PCR-product ~450 bp). G. CHO-K1 cells did not bind the NPFF receptor-specific radioligand at 
the concentration range where the positive control cell line expressing hNPFF2R showed saturable binding. The solid squares 
represent the total binding, the solid circles the nonspecific binding and the solid triangles the specific binding to the CHOK1 
cell membranes. H. The cell membranes from CHO/hNPFF2R cells were used as a positive control in the experiment. The 
open squares represent the total binding, the open circles the nonspecific binding and the open triangles the specific binding to 
the cell membranes.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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nM DPDPE and 100 nM (1DMe)NPYF showed a slight
tendency to decrease the surface fluorescence more. At 10
min time-point the treatment with 100 nM DPDPE
together with 100 nM (1DMe)NPYF (57.9 % decrease in
the cell surface fluorescence) caused significantly greater
internalization of DOR than the treatment with 100 nM
DPDPE alone (32.7 % decrease in the cell surface fluores-
cence) (Figure 3). At the 30 min time-point the cell surface
fluorescence was at a significantly reduced level after both
treatments but no significant difference was detected
between the treatments (DPDPE alone and DPDPE
together with (1DMe)NPYF).
Characterization of Tb-DeltI and its binding on whole cells
To further investigate the effects of (1DMe)NPYF on DOR
function a binding assay based on time-resolved fluorom-
etry was developed. Tb-labeled DeltI was custom-made at
Perkin Elmer Wallac. DeltI was labeled with a Tb-chelate
to the Cys-modified N-terminus of the nascent peptide.
To check whether the modification changed the affinity of
the peptide, Tb-DeltI was tested in a classical radioligand
displacement assay. Tb-DeltI displaced the 3H-diprenor-
phine from CHO/MYChDOR -cell membranes with simi-
lar affinity to the unlabeled DeltI (Figure 4A). Tb-DeltI
bound to CHO/MYChDOR cell membranes dose-
dependently and the binding was saturable at a nanomo-
lar range (Figure 4B). The results with fixed whole cells
showed similar binding characteristics as with the cell
membranes, although the absolute values were below the
ones observed with the cell membrane preparations. It
was considered that the whole cell protocol can be used to
study the effects of (1DMe)NPYF on the binding of Tb-
DeltI on CHO/MYChDOR since only relative data
between the treatments was desired. (1DMe)NPYF alone
could not significantly displace Tb-DeltI. Next the effect of
(1DMe)NPYF on the specific binding of Tb-DeltI was
studied. The total binding of Tb-DeltI on the CHO/MYCh-
DOR cells was determined in the presence of different
concentrations of (1DMe)NPYF. The unspecific binding
of Tb-DeltI was determined by 1 µM DeltI. (1DMe)NPYF
modified the specific binding of Tb-DeltI to the CHO/
MYChDOR cells. The KD for Tb-DeltI was only modestly
affected by (1DMe)NPYF whereas 1 nM and 10 nM
(1DMe)NPYF significantly decreased the BMAX  for Tb-
DeltI (Table 1). The higher concentrations of
(1DMe)NPYF affected the BMAX only modestly.
Inhibition of the forskolin induced accumulation of the 
cAMP
DOR inhibits adenylate cyclase activity in numerous tis-
sues and cell lines via coupling to Gi/o-protein. We exam-
ined the ability of the ligand-activated MYC-tagged DOR
to inhibit the forskolin stimulated cAMP accumulation in
CHO-K1 cells. As expected, already 5 min treatment of the
cells with the DOR agonist DPDPE (100 nM) reduced the
level of forskolin-stimulated cAMP significantly (Figure
5A). Similarly, the treatment with DPDPE together with
100 nM (1DMe)NPYF at this time-point and at 10 min
time-point inhibited the accumulation of cAMP.
Although there was a slight tendency for (1DMe)NPYF to
enhance the effect of DPDPE already at 5 min and 10 min
time-points, the difference between the treatments was
not significant. It was only after 30 min treatment that
(1DMe)NPYF had a robust effect on the inhibition of
cAMP induced by DPDPE (Figure 5A). At 30 min time-
point the double-treatment with DPDPE + (1DMe)NPYF
resulted in 76 % inhibition of forskolin stimulated cAMP
accumulation in comparison to 57 % inhibition when
The quantification of the cell surface fluorescence with FACS  after DOR agonist challenge: the effect of (1DMe)NPYF on  the agonist- induced internalization of DOR Figure 3
The quantification of the cell surface fluorescence 
with FACS after DOR agonist challenge: the effect of 
(1DMe)NPYF on the agonist- induced internalization 
of DOR. The cells were first treated with 100 nM DPDPE 
alone or 100 nM DPDPE + 100 nM (1DMe)NPYF or 
(1DMe)NPYF at 37°C for indicated times after which the cell 
surface receptors were detected with an anti-MYC-antibody 
and a fluorescent secondary antibody. 10000 cells/sample 
were analyzed with FACS. The combined data of five differ-
ent experiments performed in duplicates is shown. The data 
is presented as the internalization percent that is calculated 
relative to the time-matched control cells (see Experimental 
section). The statistical significance was analyzed from the 
non-normalized raw data with two-way ANOVA (Bonfer-
roni's post test, variance as SD, n = 4). *p < 0.05; **p < 0.01 
and ***p < 0.001 shows statistical significance relative to the 
basal level (untreated time-matched cells), †††p < 0.001 signif-
icant change in cell surface fluorescence between treatments. 
The dashed bars represent cells treated with 100 nM DPDPE 
alone, the solid bars cells treated with 100 nM DPDPE + 100 
nM (1DMe)NPYF and the dotted bars represent the cells 
with 100 nM (1DMe)NPYF alone.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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treating the cells with DPDPE alone. (1DMe)NPYF alone
did not have any significant effect on the amount of
cAMP. Both the effect of DPDPE and DPDPE +
(1DMe)NPYF was completely blocked by the pre-treat-
ment with pertussis toxin (Figure 5A). (1DMe)NPYF was
also able to enhance the inhibitory effect of other DOR
agonists, e.g. DeltI, on the cAMP accumulation (data not
shown), indicating that the modulatory effect of
(1DMe)NPYF on the inhibition of cAMP accumulation is
not agonist specific.
The effect of (1DMe)NPYF dose on the inhibitory action
of DPDPE on the cAMP accumulation was also studied.
The cAMP accumulation was measured at 30 min time-
point. Above 100 nM DPDPE the cAMP inhibition
reached saturation and addition of higher concentration
of DPDPE did not result in further inhibition of forskolin
stimulated cAMP accumulation (Figure 5B &5C).
The binding of Tb-DeltI to CHO/MYChDOR -cells Figure 4
The binding of Tb-DeltI to CHO/MYChDOR -cells. A. Tb-DeltI can displace 3H-diprenorphine with similar affinity as 
unlabeled DeltI. In the competitive binding experiment 0.1 nM – 10 µM Tb-labeled DeltI or native DeltI was used to displace 
6.86 nM3H-diprenorphine from the CHO/MYChDOR cell membranes. Tb-DeltI displaced the radioligand with a similar affinity 
as the unlabeled native DeltI. The solid line (curve fit) and the crosses represents the competitive binding for DeltI; the dashed 
line and the open circles for Tb-DeltI. The data is presented as the specific binding (SB) relative to the total binding (TB). The 
specific binding depicts the radioligand binding that can be displaced by the competing ligand (DeltI or Tb-DeltI). B. Tb-DeltI 
shows specific, saturable binding to DOR binding sites. The nonspecific binding of Tb-DeltI to CHO/MYChDOR -cells was 
determined in the presence of 1 µM DeltI. The binding of Tb-DeltI was saturable at a nanomolar range. The data is presented 
as the specific binding (SB) relative to the total binding (TB). The specific binding depicts the binding of Tb-DeltI that can be dis-
placed by the unlabeled ligand.
Table 1: The effect of (1DMe)NPYF on the specific binding of Tb-
DeltI on CHO/MYChDOR cells. The KD and BMAX values for Tb-
DeltI binding were determined in the presence of different 
concentrations of (1DMe)NPYF. Native DeltI (1 µM) was used to 
determine the nonspecific binding. Statistical significances were 
calculated relative to specific binding in the absence of 
(1DMe)NPYF (one-way Anova, ***p < 0.001, n = 3). The values in 
the table are from whole cell assays and therefore provide only 
relative information about the KD and BMAX values between 
treatments.
(1DMe)NPYF (nM) KD(nM) BMAX(pmol/cell)*
0 75.8 ± 8.1 1.60 ± 0.06
1 52.1 ± 6.5 0.70 ± 0.08 ***
10 55.5 ± 7.6 0.89 ± 0.06 ***
100 82.5 ± 3.9 1.42 ± 0.11
1000 80.5 ± 8.2 1.49 ± 0.10
*Relative BMAX-values from whole cell binding experiments; calculated 
as pmol/cell.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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(1DMe)NPYF enhances the DOR agonist induced inhibition of forskolin stimulated cAMP accumulation in the CHO-cells  expressing MYChDOR Figure 5
(1DMe)NPYF enhances the DOR agonist induced inhibition of forskolin stimulated cAMP accumulation in the 
CHO-cells expressing MYChDOR. A. The %-cAMP inhibition was calculated relative to the amount of cAMP in the cells 
treated with only forskolin. The cells were treated at 37°C for the indicated times with 10 µM forskolin together with 100 nM 
DPDPE (dashed bars), with 100 nM DPDPE + 100 nM (1DMe)NPYF (black solid bars) or with 100 nM (1DMe)NPYF (white 
solid bars). The bars next to each treatment at each time-point represent the cells pre-treated with pertussis toxin (+PTX). 
The statistical significance between treatments and time-points is shown in the figure (two-way ANOVA with Bonferroni's post 
test, variance as SD; significance relative to forskolin only treated cells ***p < 0.001; significance between treatments ††p < 
0.01, n = 6). B. The effect of (1DMe)NPYF dose on the DPDPE-induced cAMP-inhibition. The cells were stimulated at 37°C 
for 30 min with 10 µM forskolin together with 0.1 nM – 10 µM DPDPE and 0 nM – 1 µM (1DMe)NPYF. (1DMe)NPYF caused 
a significant increase in the DPDPE-induced inhibition of cAMP (two-way Anova, variance as SD; DPDPE p < 0.001; 
(1DMe)NPYF p < 0.001, [DPDPE] × [(1DMe)NPYF p < 0.01, n = 3). The post-hoc test showed that 10 nM (p < 0.05) and 100 
nM (p < 0.05) (1DMe)NPYF had a significant effect on the DPDPE induced cAMP inhibition. The solid circles with thick line 
represent the cells treated with 0.1 nM – 10 µM DPDPE alone, the open triangles cells treated with DPDPE together with 10 
nM (1DMe)NPYF, and the solid squares cells treated with DPDPE together with 100 nM (1DMe)NPYF. C. 1 nM (1DMe)NPYF 
and 1 µM had only minor effects on the DPDPE induced cAMP inhibition. The solid circles with thick line represent the cells 
treated with 0.1 nM – 10 µM DPDPE alone, the solid triangles cells treated with DPDPE together with 1 nM (1DMe)NPYF and 
the open squares DPDPE together with 1 µM (1DMe)NPYF.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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(1DMe)NPYF had a significant effect on the DPDPE-
induced cAMP inhibition (two-way Anova, DPDPE p <
0.001; (1DMe)NPYF p < 0.001, [DPDPE] × [(1DMe)NPYF
p < 0.01, n = 3). More specifically, 10 nM and 100 nM
(1DMe)NPYF together with DPDPE enhanced the DOR
agonist induced inhibition of cAMP accumulation signif-
icantly at all tested DPDPE concentrations (Figure 5B)
whereas the lowest and highest tested concentrations of
(1DMe)NPYF had hardly an effect on the cAMP accumu-
lation (Figure 5C).
Activation of MAP-kinase signaling pathway
The activation of MAP-kinase p42MAPK (ERK2) is charac-
terized by the appearance of the phosphorylated form of
the ERK2. The phosphorylated ERK2 was detected on the
immunoblots after the cells were treated with DPDPE,
(1DMe)NPYF or both for 0, 5, 10 and 30 minutes at 37°C.
The basal level (t = 0 min) of phosphorylated ERK2 was at
the detection limit of the antibody and only a very faint
band could be detected (Figure 6A, left-most lane). When
quantified, this band did not markedly differ from the
background. The treatment of the cells with (1DMe)NPYF
alone did not result in the activation of ERK2 (Figure 6A,
right panel). Neither did any of the treatments signifi-
cantly affect the total amount of ERK2. The total ERK2 was
controlled from the immunoblots with an antibody
detecting the unphosphorylated form of the kinase, which
was compared to the amount of tubulin in each sample.
DPDPE (100 nM) activated the MAPK pathway as
expected (Figure 6A and 6B). The peak in activation was
observed after 10 minutes DPDPE-treatment followed by
a decrease in the amount of the phosphorylated kinase.
The addition of (1DMe)NPYF (100 nM) together with
DPDPE (100 nM) significantly promoted the activation
induced by DPDPE. The peak in activation with DPDPE +
(1DMe)NPYF was detected already after 5 min in contrast
to 10 min peak-activation time for DPDPE alone. At 10
min time-point there was no significant difference in the
amount of phosphorylated ERK2 between DPDPE and
DPDPE + (1DMe)NPYF-treated cells. However, at this
time-point the level of phosphorylated ERK2 in the
DPDPE + (1DMe)NPYF-treated cells had already started
to decline whereas in the DPDPE-treated cells the level of
phosphorylated ERK2 was still increasing when compared
to the earlier and later time-points. In both DPDPE-
treated cells and DPDPE + (1DMe)NPYF-treated cells after
30 minutes agonist stimulation the level of activated
ERK2 had almost decreased back to basal values.
Discussion
NPFF's role in physiological pain sensation and opioid
analgesia is well characterized. Some of the NPFF's pain-
related effects are mediated by the delta opioid receptor
system [for review see ref. [8]]. In this study we examined
the role of NPFF in the modulation of DOR-mediated cel-
lular responses. We wanted to establish a simple model
system to study the effect of NPFF analogue,
(1DMe)NPYF, on the DOR function in the absence of
NPFF receptors. We generated a cell line expressing N-ter-
minally c-MYC-epitope tagged human DOR at close to
physiological expression levels (see below). We also veri-
fied that the cells do not express functional NPFF
receptors.
The expression level and binding affinity of the selected
CHO/MYChDOR clone was within the same range as that
reported for the well-studied NG108-15 neuroblastoma
cell line [34] and for some native neuronal tissues e.g. rat
striatum [35]. At this expression level the receptor traffick-
ing and cellular signaling of the cells are expected to be
normal but extreme over expression of a receptor might
disrupt the functional properties of the cells. The cells
responded to DOR ligands as expected in two different
functional assays and the ligands also induced the inter-
nalization of DOR. In the basal state, some receptors were
found in the internal parts of the cells, which is consistent
with the previous findings for the delta opioid receptor
[36]. Taken together, the pharmacological studies and
confocal microscopic analysis together with functional
assays suggested that the N-terminal modification of
hDOR did not affect the ligand selectivity, functional cou-
pling or trafficking of the expressed receptors.
DOR belongs to the large family 1 of GPCRs. We hypoth-
esized that instead of, or in addition to operating via indi-
rect mechanisms, NPFF could have a direct modulatory
effect on DOR. Compounds that modulate the receptor
activation have been described for other members of the
receptor family [for a review see ref. [37]]. Modulators can
potentate or block the agonist stimulation of the receptor
in many ways, such as by changing the agonist affinity or
stability of receptor-G-protein interaction [38-40].
Our FACS studies showed that in the presence of
(1DMe)NPYF the agonist-induced internalization of DOR
was enhanced. The increase in the receptor internalization
by (1DMe)NPYF was most obvious after 10 min agonist
exposure. The DOR antagonist naltrindole could com-
pletely block, not only the receptor activation by DOR
agonists alone, but also the enhanced activation resulting
from the co-application of (1DMe)NPYF with DOR ago-
nists. This provides evidence that the observed effects were
solely DOR-mediated. In vivo many of the analgesic effects
of NPFF are blocked by both the non-specific opioid-
antagonist naloxone and the DOR-specific antagonists
naltrindole [4,44]. The differences between time-points
and treatments in the FACS analysis were consistent and
reproducible as assessed with statistical methods.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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DOR agonist induced phosphorylation of the MAP-kinase, ERK2, is increased by (1DMe)NPYF Figure 6
DOR agonist induced phosphorylation of the MAP-kinase, ERK2, is increased by (1DMe)NPYF. A. Total cell 
lysates (10 µg protein per lane) were detected with phosphoERK2 and total ERK2 specific antibodies. The equal loading of 
samples was controlled with anti-tubulin antibody. The cells were treated with 100 nM DPDPE alone (left panel), with 100 nM 
DPDPE together with 100 nM (1DMe)NPYF (middle panel) or with 100 nM (1DMe)NPYF (right panel) for 5, 10 or 30 min. 
(1DMe)NPYF alone could not induce the phosphorylation of ERK2 above the basal level. The data shown are representative 
figures of five independent experiments. B. The band intensities of phosphoERK2 were quantified and they are presented as 
relative band intensities with respect to the total ERK2. The dashed bars represent the cells treated with 100 nM DPDPE alone 
and the solid bars cells treated with 100 nM DPDPE and 100 nM (1DMe)NPYF. The statistical significance between time-points 
and treatments was analyzed with two-way Anova with Bonferroni's post-test, n = 5. Both of the treatments significantly 
induced the phosphorylation of the ERK2 above the basal level at all time-points (***p < 0.001). The difference between treat-
ments was significant at the first time-point tested (††p < 0.01).BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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To study the effect of NPFF in DOR systems, we intro-
duced a new tool to study the interactions between recep-
tors and their ligands. A Tb-labeled DOR-ligand was used
in a time-resolved fluorescence based binding assay and it
proved comparable to the traditional radiolabel-based
methods. Tb-DeltI could be applied to both cell mem-
brane and whole cell assays. This new ligand and other
related compounds open interesting possibilities to fur-
ther study the ligand-receptor interactions, by using meth-
ods such as time-resolved FRET. Our results from the
time-resolved fluorescence based binding assays indicate
that NPFF can modulate the binding of DOR ligands to
the receptor. Consistent with the earlier reports with spi-
nal cord membranes [16], (1DMe)NPYF did not markedly
bind to the classical DOR-binding site in the CHO/MYCh-
DOR cells. Only micromolar concentration of
(1DMe)NPYF could displace Tb-DeltI in whole cell and
membrane binding assays to some extent. The binding
experiments showed that (1DMe)NPYF affected the KD of
Tb-DeltI only slightly, whereas the BMAX values were sig-
nificantly decreased by low to modest concentrations of
(1DMe)NPYF. It should be noted that the effects of
(1DMe)NPYF on ligand binding observed in assays using
a labeled agonist Tb-DeltI were partly verified by using a
labeled antagonist, 3H-diprenorphine, as the ligand. In
addition, while most of the experiments were performed
with whole cells, a protocol that mimics the cellular envi-
ronment for the natural receptor binding, the results were
also to some extent confirmed with cell membrane prep-
arations. This was to avoid the contribution of possible
endogenous effector molecules present in whole cells.
The lack of change in the KD for opioid ligands implies
that especially at low concentrations (1DMe)NPYF does
not work through the classical opioid binding site of
DOR. The dose-dependence of NPFF-agonist on the BMAX
was bell-shaped. This could imply that the NPFF-analogue
affects only some conformations of the receptor. Interest-
ingly, also the effect of NPFF on prolactin release from rat
pituitary cells show a bell-shaped dose-response curve
[41]. However, the receptor involved in the prolactin
release mechanism was not characterized. The NPFF-ana-
logue had an effect on the BMAX at lower concentrations
(1–10 nM) than on the signaling cascades studied. This
could be related to the mechanism of the functional mod-
ulation of DOR by the NPFF-analogue. One possible
mechanism could involve a modulatory binding site for
NPFF on DOR. Modulatory binding sites have been
described for other members of the GPCR family [37-40].
In line with our results, the GPCR modulators exert their
effects commonly only in the presence of the receptor lig-
and [37]. In the future, the exact nature of interactions
between DOR and NPFF will be further studied.
The modulatory effect of (1DMe)NPYF on DOR-mediated
signaling was studied by measuring the activation of two
differently regulated signaling cascades. The signaling
studies suggested that (1DMe)NPYF alone did not affect
DOR function but when applied together with a DOR
agonist it significantly promoted the response of the acti-
vated signaling cascade. (1DMe)NPYF could enhance the
DOR agonist induced inhibition of forskolin-stimulated
cAMP accumulation, a signaling cascade primarily regu-
lated by the Gi/oα -subunit. The signaling via DOR was
most strongly affected by (1DMe)NPYF at low to modest
concentrations of DOR agonist. The cAMP inhibition
resulting from double treatment with DPDPE +
(1DMe)NPYF was greater than inhibition obtained by
treatment with DPDPE alone at a broad DPDPE concen-
tration range with various concentrations of the NPFF
analogue. Also the maximal cAMP inhibition obtained
with the double treatment was greater than that observed
after treating the cells with a DOR agonist alone.
In addition to the regulation of cAMP levels,
(1DMe)NPYF enhanced the DOR agonist-induced phos-
phorylation of ERK2, a member of MAP-kinase family.
The activation ERK2 phosphorylation follows a series of
activation steps initiated by the Gβγ -subunit. Interest-
ingly, in the cells subjected to (1DMe)NPYF together with
a DOR agonist an earlier peak in activation of ERK2 was
observed than in cells treated with a DOR agonist alone.
The finding that NPFF affects two differently regulated sig-
naling cascades downstream from G-protein activation
gives support for our hypothesis that NPFF works at the
receptor level, prior to the G-protein activation. Both the
DOR agonist-induced activation of receptor-mediated sig-
naling and the enhanced activation caused by the addi-
tion of (1DMe)NPYF together with DOR agonist were
completely blocked by PTX, giving evidence that NPFF
delivers its effects via the same G-proteins as the DOR ago-
nists binding to the classical binding site.
The enhancement of the DOR-mediated signaling could
be due to the increased receptor trafficking. The acceler-
ated internalization of the membrane-bound receptors
could account for the enhanced signaling observed. The
effect of (1DMe)NPYF on the internalization of DOR was
transient and relatively small. There is some evidence that
DOR ligands can affect the balance between receptors
located on the cell membrane and receptors residing in
the internal parts of the cells [45,46]. Petäjä-Repo et al.
[45] have shown that DOR ligands can work as molecular
chaperones, i.e. ligand binding to the receptor induces the
transport of receptors to the membrane. It is likely that
also the increased recruitment of the receptors from the
internal pools to the cell membrane could account for the
observed effects. Cahill et al. [46] showed that enhanced
antinociceptive activity of DeltI is correlated with theBMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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recruitment of spinal opioid receptors from intracellular
stores to the plasma membrane and that inflammation, a
state that activates DOR -mechanisms, produces outward
movement of intracellular DORs towards the plasma
membrane. Therefore, the observed rate of internalization
may be masked to some extent by the recruitment of the
receptors from the internal pools. It should be noted that
all the phenomena described above were observed with
both the peptidic agonist DeltI and the cyclic agonist
DPDPE. This implies that the effect is not between the
agonists and (1DMe)NPYF but rather that (1DMe)NPYF
modifies the receptor and alters its characteristics.
Conclusion
Our results suggest that some of the NPFF's antinocicep-
tive effects and interactions with opioid systems could at
least in part be mediated directly via DOR. The agonist-
induced internalization of DOR and the DOR mediated
signaling are enhanced by NPFF, the specific binding of
ligands to DOR is modified by NPFF. All changes
observed in the different assays were in agreement with
each other, although they had a bit different time-courses,
and they all support the suggested direct interaction
between NPFF and the DOR-ligand complex. The differ-
ent time-course of events could be due to the various reg-
ulatory mechanisms involved. For example, the
inhibition of the adenylate cyclase activity is directly regu-
lated by the Gi/o-protein α -subunit and the phosphoryla-
tion of ERK2 is mainly activated by the Gβγ  subunit. The
observed effects are also physiologically relevant, as pub-
lished data suggest that opiate-induced analgesia is poten-
tiated by NPFF [44], and the DOR antagonist naltrindole
inhibits the NPFF-induced antinociception [4]. Although
the modulatory effect of (1DMe)NPYF was moderate or in
some cases quite small, it was consistently observed with
all methods used in this study. As mentioned earlier,
CHO-K1 cells do not express detectable levels of NPFF
receptors. Therefore, DOR alone could be responsible for
the modulatory effects of (1DMe)NPYF observed in this
study. The results were obtained using a heterologous
expression system and therefore they cannot be directly
extended to in vivo conditions. Recent data based on opi-
oid knockout mice show that DOR is mainly involved in
the inflammatory and mechanical nociception [47]. NPFF
expression is also significantly increased in inflammatory
pain [3], and NPFF modulates descending inhibitory
input to the wide-dynamic range neurons [8]. Some of the
effects of NPFF in pathological pain and interactions with
morphine may be mediated via DOR. This does not
exclude e.g. the possible involvement of NPFF2R in pain
mechanisms [18]. As two receptors for NPFF have been
characterized, it seems likely that NPFF can have several
functions depending on the site of action and availability
of receptors. NPFF may be a multi-functional neuropep-
tide capable of affecting several neuronal systems through
different receptors and signaling pathways, the effects
depending on the other players present at the site action.
Methods
Materials
Cell culture medium components were from BioWhit-
taker (East Rutherford, NJ, USA), Sigma-Aldrich (St. Louis,
MO, USA) or Gibco BRL/Invitrogen (Carlsbad, CA, USA).
Blasticidin S HCl was from Invitrogen and FuGene 6 from
Roche (Basel, Switzerland). [D-Pen(2,5)]enkephalin
(DPDPE) and naloxone were purchased from Sigma. Del-
torphin I (Y-D-AFDVVG-NH2) was from Bachem (Buben-
dorf, Switzerland). (1DMe)NPYF (D-YL-(NMe)-FQPQRF-
NH2) was either custom-synthesized (Peptide Technolo-
gies, Gaithersburg, MD, USA) or from Bachem. Tb-labeled
DeltI was custom made at Wallac (Perkin Elmer Wallac,
Turku Finland) and all the reagents for the time-resolved
fluorometry were purchased from Wallac. Mouse mono-
clonal anti-c-MYC antibody 9E10 and the c-MYC blocking
peptide were from Sigma-Aldrich, rabbit polyclonal anti-
c-MYC 9E10 antibody was from Santa Cruz Biotechnolo-
gies (Santa Cruz, California, USA), rabbit polyclonal C-
terminal and N-terminal anti-NPFF2R antibodies and
blocking peptides from Novus Biologicals (Littleton, CO,
USA), rabbit anti-phospho-ERK1/2 antibody from Cell
Signaling Technology (Beverly, MA, USA), mouse anti-
ERK2 antibody from BD Transduction Laboratories (Bec-
ton Dickinson and Company, Franklin Lakes, NJ, USA),
mouse anti-tubulin antibody from NeoMarkers (Fremont,
CA, USA), goat anti-mouse Alexa 488 and goat anti-rabbit
Alexa 488 antibodies from Molecular Probes (Eugene,
Oregon, USA), goat anti-mouse horse radish peroxidase
(HRP) and goat anti-rabbit-HRP conjugates from Bio-Rad
(Hercules, California, USA). Nitrocellulose membrane
was obtained from Schleicher & Schuell (Keene NH,
USA). Enhanced chemiluminescence (ECL) reagents, 125I-
(1DMe)NPYF and 3H-diprenorphine were from Amer-
sham Pharmacia Biotech (Uppsala, Sweden). Restriction
enzymes and other molecular biology products were pur-
chased from Promega (Madison, WI, USA) or New Eng-
land Biolabs (Beverly, MA, USA), PCR-primers were from
Sigma Genosys (St. Louis, MO, USA). The CHO-K1/
hNPFF2 cell membranes were from EuroScreen S.A. (Brus-
sels, Belgium). The AcroWell filter plates were from Pall
Life Sciences (NY, USA). General laboratory reagents were
from Sigma-Aldrich or Merck (Darmstadt, Germany).
Plasmid construction, transfection and cell culture
The human delta opioid receptor (a kind gift from Dr.
Brigitte Kieffer) was N-terminally tagged with c-MYC-
epitope (EQKLISEEDL). The coding sequence was ampli-
fied with primers that added the c-Myc epitope tag, a
Kozak-sequence and an NheI-site immediately upstream
of the hDOR and a BstXI-site downstream of the receptor
sequence. The PCR-product was inserted into NheI/BstXI-BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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site of the vector pcDNA6.0A (Invitrogen) and the con-
struct was verified by sequencing. The human NPFF2R
gene was cloned from human placental total RNA by RT-
PCR. The full- length coding sequence was further sub-
cloned into the pcDNA6.0A (Invitrogen) with similar
methodology as that used for hDOR (instead of c-MYC
tag, a FLAG tag was inserted N-terminally) and the con-
struct was verified by sequencing.
The pcDNA6.0A-FLAGhNPFF2R construct was used for
transient transfection of Chinese hamster ovary cells defi-
cient in dihydrofolate reductase (CHO-K1, dhfr-). The
plasmid was transfected into CHO-K1 cells with FuGene 6
reagent according to the supplier's instructions and 24 h
post-transfection the cells were used for
immunocytochemistry.
To create a stable cell line expressing c-MYC tagged
human DOR, the pcDNA6.0A-MYChDOR vector con-
struct was linearized with SspI and the linear DNA was
used to transfect CHO-K1 cells. The stable transfection
was performed using FuGene 6 reagent according to sup-
plier's instructions. A stable clone expressing the receptor
at the desired level was selected using FACS analysis. The
cells were incubated with rabbit-anti-MYC in PBS supple-
mented with 1 % normal goat serum (v/v) on ice, washed
with ice-cold PBS and further incubated with the goat
anti-rabbit Alexa 488 antibody in PBS on ice. After washes
with ice-cold PBS the cells were suspended in PBS supple-
mented with 10 % fetal calf serum (v/v) and sorted. After
expansion the obtained cells were plated onto 96-well
plate and clones originating from a single cell were
selected. The clones were analyzed for the receptor
expression with immunocytochemistry and radioligand
binding and the functionality of the heterologously
expressed receptor was tested with MAPK and cAMP -
assays.
The expression of NPFF receptors in CHO-K1 cells was
tested with reverse-transcription polymerase chain reac-
tion (RT-PCR). Total RNAs from wild type CHO-K1 cells
and the CHO-K1 clone expressing MYC-tagged DOR were
isolated with RNAwiz protocol (Ambion). Total RNA
from human placenta and human medial hypothalamus
were isolated and were used as positive controls in RT-
PCR. cDNA from the total RNA was produced with The
Superscript First-Strand Synthesis System for RT-PCR (Inv-
itrogen). The expression of NPFF receptors was analyzed
with several primer pairs specific for either human or
mouse receptors (the receptors from hamster have not
been cloned). Sequences for the primers specific for the
human NPFF2R were: 5'-GAT TGG TCC AGG GAA TAT
CTG TC-3' and 5'-CAG TGT GCA AAA GGG TAG ATG
TAG-3' or 5'-GGA TGG CCA TTT GGA AAC-3' and 5'-CCA
ATC CTT CCA TAC ATG-3'. Sequences for the primers spe-
cific for the human NPFF1R were 5'-CGA CAA TGC CAC
ATG CAA GAT GAG-3' or 5'-CGC AAC CGC TCC TAC
CCT CTC TAC-3' together with 5'-AGG GGA AGG CGT
AGA CGG TGA C-3'. Corresponding mouse specific prim-
ers were also used in the analysis.
CHO-K1 cells were cultured in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10 % (v/v)
FBS, 4.5 g/litre glucose, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 1 mM glutamine and 1 × HT-supplement.
For the transfected cells the selection pressure was main-
tained by adding 0.5 µg/ml Blasticidin S HCl to the cul-
ture media. The cells were kept at 37°C in 5 % CO2/
humidified air and the culture medium was changed every
3–4 days. The cells were sub cultured in ratio of 1:5–1:10
and only cells undergone fewer than 20 passages were
used for the experiments.
Immunocytochemistry and confocal microscopy
The cells were collected, plated onto 18 mm × 18 mm
cover slips and cultured o/n. After o/n incubation the cells
were rapidly cooled on ice, the medium was removed and
the cells were washed two times with ice-cold PBS. The
cells were fixed with 4 % PFA (w/v) for 30 min at +4°C
and washed twice with PBS. The fixed cells were first incu-
bated with 1 % normal goat serum (v/v); with or without
0.05 % saponin (w/v) in PBS for 30 h at +4°C and then o/
n with 1:5000 dilution of mouse anti-c-MYC/1:2000 dilu-
tion of rabbit anti-NPFF2R antibody in 1 % normal goat
serum (v/v) in PBS. After washes with PBS the cells were
incubated with 1:1000 dilution of goat anti-mouse/anti-
rabbit Alexa 488 antibody in PBS for 1 h at +4°C. They
were then washed with PBS and the cover slips were
mounted onto objective glasses.
The slides were analyzed with a Leica TCP-SC laser scan-
ning microscope system with Ar-Kr laser (Omnichrome,
Melles Griot, Carlsbad, CA, USA). The images were
acquired and processed with Leica TCS NT/SP Scanware
software. The excitation and emission wavelengths used
were for the Alexa 488 secondary antibody excitation 488
nm and emission 492–540 nm. The samples were
scanned with identical settings taking images every 0.5
µm. The PMT values for the laser scanner were set with a
negative control slide, i.e. autofluorescence was elimi-
nated. The image representing the mid-nuclear level of the
scanned sample was taken from the image stack for a com-
parative analysis between time-points and treatments. The
scanned images were further analyzed and the figures for
the publication were produced with Adobe Photoshop
6.0 (Adobe Systems, San Jose, CA, USA) and/or Corel
Draw 9.0 software (Corel, Ottawa, Canada). Each image
was again treated similarly and the figures were not
manipulated in any way. Representative images were cho-
sen for the Figures 1 and 2.BMC Neuroscience 2005, 6:21 http://www.biomedcentral.com/1471-2202/6/21
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Flow cytometry
The CHO/MYChDOR cells were collected and suspended
into the culture medium. The cells were treated with drugs
in suspension as for the immunocytochemistry for the
indicated times. After the incubation, the membrane traf-
ficking was stopped by rapidly chilling the cells on ice and
removing the medium. After this the cells were kept on
ice. The cells were washed with PBS and stained in PBS-
suspension with rabbit anti-MYC antibody (1 % normal
goat serum (v/v) used to block unspecific binding), fol-
lowed by the detection with a fluorescent secondary anti-
body. Dead cells were detected with isopropidium iodide.
Cells were analyzed with FACScan flow cytometer (Becton
Dickinson and Co., Mountain View, CA, USA). Data from
10000 cells were collected for each run and each sample
was run in replicate or triplicate.
The internalization percent was calculated as:
 where F(ctrl) in the fluores-
cence of the time-matched control cells and the F(sample)
is the fluorescence measured from the drug-treated cells.
Determination of intracellular cAMP levels
50000 cells/well seeded onto 96-well plates and incu-
bated o/n. In the case of pertussis toxin pre-treatment, the
cells were incubated 16–20 h with 100 ng/ml PTX before
the exposure for drugs. The cells were incubated for one
hour with serum-free medium at 37°C; then 0.3 mM 1-
Methyl-3-isobutylxanthine (IBMX) and 0.3 mM
indomethazine were added and the cells were further
incubated for 10 min. After this 10 µM forskolin was
added with or without the drugs (DPDPE, (1DMe)NPYF
or DPDPE + (1DMe)NPYF). The cells were incubated for
the indicated times at 37°C, the reaction was stopped by
adding lysis buffer (supplied by the kit) and cooling the
cells on ice. The amount of cAMP was determined from
the cell lysates with Delfia cAMP kit (Perkin Elmer Wallac,
Turku, Finland). The time-resolved fluorescence was
measured with Victor2 Multilabel counter (Perkin Elemer
Wallac, Turku, Finland).
Phosphorylation of MAPK
25000 cells/well were seeded onto 24-well plates and
incubated o/n. The medium was replaced with serum-free
medium and the cells were incubated for one hour at
37°C. Serum-free medium containing 100 nM DPDPE or
100 nM (1DMe)NPYF or 100 nM DPDPE + 100 nM
(1DMe)NPYF (end concentrations) was added and the
incubation was continued for the times indicated. The
reaction was stopped by removing the medium and add-
ing modified RIPA-lysis buffer (PBS, pH 7.6; 1 % Nonidet
P-40 (v/v); 0.5 % sodium deoxycholate (w/v); 0.1 % SDS
(w/v), 10 mM NaF; 0.4 mM PMSF, 10 µg/ml aprotinin, 10
µg/ml leupeptin, 2 mM Na2VO5; 0.2 mM bestatin). Cells
were lysed on ice for 15 min and the lysates were col-
lected. The protein content was determined with the Brad-
ford method.
10 µg of protein was analyzed on 10 % SDS-PAGE gel and
the gel was blotted onto nitrocellulose membrane. The
membrane was blocked with 5 % fat-free dry milk (w/v)
in TBS-T (10 mM Tris/HCl pH 7.6; 150 mM NaCl; 0.05 %
Tween 20 (v/v)). It was then incubated with 1:2000 dilu-
tion of rabbit anti-phospho-ERK1/2 antibody in the
blocking buffer o/n at 4°C, washed with TBS-T, incubated
for one hour at room temperature with 1:3000 dilution of
goat anti-rabbit-IgG conjugated to HRP in the blocking
buffer. After washes, the membrane was detected with the
ECL-protocol. The band intensities were measured with
AlphaDigiDoc1000 documentation system (Alpha
Innotech, San Leandro, CA, USA).
After stripping with 0.2 M glycine; 0.5 M NaCl, pH 2.5 the
membrane was similarly stained with mouse anti-ERK2
(1:5000 dilution) and mouse anti-tubulin (1:1000 dilu-
tion) antibodies to determine the total amount of ERK2
and to control the equal loading of samples, respectively.
Goat anti-mouse-IgG conjugated to HRP (1:3000 dilu-
tion) was used as the secondary antibody.
Preparation of cell membranes
The cells were collected with PBS + 0.2 % EDTA (w/v) and
washed with cold PBS. The CHO/MYChDOR or CHO-K1
cells were suspended into ice-cold 50 mM Tris/HCl, 5 mM
EDTA, pH 7.5 and homogenized with Potter S-homogeni-
sator on ice. The homogenate was centrifuged 47800 × g
at 4°C and the pellet was suspended into the Tris/EDTA
buffer and the homogenization/centrifugation was
repeated. The pellet was suspended into cold binding
assay incubation buffer and the protein content was meas-
ured with the Bradford method.
Radioligand binding on cell membranes
The binding experiments were performed as described in
[21]. 25 µg or 50 µg of crude membrane preparation pre-
pared as described above was used per assay. As positive
control membrane preparation from EuroScreen S.A.
(Brussels, Belgium) was used. For the saturation binding
assay the membranes were incubated for one hour at
room temperature with 0.2–10 nM 3H-diprenorphine in
50 mM Tris/HCl, pH 7.5 or 0.002 – 0.2 nM 125I-
(1DMe)NPYF in the binding buffer described in [21]. The
non-specific binding was determined with 10 µM
naloxone for 3H-diprenorphine and with 1 µM
(1DMe)NPYF for 125I-(1DMe)NPYF. In the displacement
assays the effect of 0.1 nM – 10 µM DPDPE and/or
(1DMe)NPYF on 6 nM 3H-diprenorphine binding was
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determined. Otherwise, the assay conditions were as for
the saturation assay.
Tb-DeltI binding on cell membranes and whole cells
6 µg of crude membrane preparations or whole cells (25
000 cell/well) that were plated one day before experiment
and fixed with 4 % PFA for 10 min at room temperature,
were used in the saturation binding experiments. The
whole cell assays were carried out on normal cell culture
plates and the assays with membrane preparations on spe-
cial filter plates (Pall Life Sciences). The cells or mem-
branes were incubated in 50 mM Tris/HCl pH 7.5; 2.5
mM MgCl2; 60 mM NaCl; 25 µM EDTA, 0.2 % BSA (w/v)
for 90 min at room temperature with 0.01 – 781.25 nM
Tb-DeltI in the presence or absence of 1 or 5 µM unla-
beled DeltI. To study the effect of (1DMe)NPYF on the Tb-
DeltI binding, 1–1000 nM (1DMe)NPYF was added
together with unlabeled DeltI. After the incubation the
unbound Tb-DeltI was removed by washing the plates
four times with 50 mM Tris/HCl pH 7.5; 2.5 mM MgCl2.
Vacuum pump system was used to wash the filter plates.
Since the chelate-bound Tb-ion is nonfluorescent, it
needed to be released from the complex. In order to
release Tb-ion from the chelate 150 µl Delfia enhance-
ment solution was added to the wells and the plates were
incubated on a shaker for 15 min. Thereafter, 40 µl Delfia
enhancer that changes the pH of the assay solution appro-
priate for Tb-fluorescence was added, and the plates were
further incubated for 5 min on a shaker. The time-
resolved fluorescence of the released Tb-ion was measured
with Victor2 Multilabel counter (Perkin Elemer Wallac,
Turku, Finland).
Statistics
All the experiments were repeated at least three times with
three replicates in all assays. Prism GraphPad Softwear
version 4.0 (GraphPad Softwear, San Diego, CA, USA)
was used for all statistical analysis. Two-way Anova with
Bonferroni's post-test or one-way Anova with Bonferroni's
multiple comparison test was used to assess the statistical
significance of the binding assay, cAMP-assay, MAPK-
assay and FACS-analysis results. When a parametrical test
was used the analysis was done on the raw, non-normal-
ized data.
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